a Department of Ophthalmology , University Medicine Charité, Campus Virchow Clinic , Berlin , Germany.
Ocul Immunol Inflamm. 2018;26(1):160-165. doi: 10.1080/09273948.2016.1196712. Epub 2016 Jul 20.
To assess the efficacy and tolerability of intravitreal dexamethasone 0.7 mg sustained-release insert (Ozurdex) in patients with sclerouveitis and recurrent cystoid macula edema (CMO) refractory to treatment.
Interventional retrospective case series of five patients receiving 13 intravitreal dexamethasone inserts.
Three of five patients presented with an associated systemic disorder, whereas two patients had idiopathic sclerouveitis. All patients received immunosuppressive therapy. The CRT mean (SD) decreased in all eyes from 428 μm (137) (baseline) to 327 μm (149) (1 month), 342 μm (155) (3 months), 297 μm (99) (6 months) and reduced scleral inflammation. No morphologic adverse changes were noted, in particular, no scleral melting or necrosis occurred.
Intravitreal dexamethasone may be an effective and safe therapeutic option in sclerouveitis with otherwise treatment-resistant CMO. It resolves not only CMO, but also provides a reduction of scleral inflammation and ocular pain. Nonetheless, adequate immunosuppressive treatment of an underlying disease must ensue.
评估玻璃体内注射地塞米松 0.7mg 缓释植入剂（Ozurdex）治疗葡萄膜炎伴复发性囊样黄斑水肿（CMO）的疗效和耐受性，这些患者对治疗有抗药性。
对接受 13 次玻璃体内注射地塞米松的 5 名患者进行回顾性干预病例系列研究。
5 名患者中有 3 名伴有系统性疾病，2 名患者为特发性葡萄膜炎。所有患者均接受免疫抑制治疗。所有患者的 CRT 平均值（SD）均从基线时的 428μm（137）降至 1 个月时的 327μm（149）、3 个月时的 342μm（155）、6 个月时的 297μm（99），巩膜炎症减轻。未观察到形态学不良反应，特别是没有发生巩膜融解或坏死。
玻璃体内注射地塞米松可能是治疗复发性 CMO 且对其他治疗有抗药性的葡萄膜炎的有效且安全的治疗选择。它不仅可以解决 CMO，还可以减轻巩膜炎症和眼部疼痛。尽管如此，仍必须进行适当的潜在疾病的免疫抑制治疗。
